
|Articles|January 1, 2003
Physicians Assess Injectable
Author(s)Mark Blanchard
Toronto - A group of Canadian physicians who use Artecoll, an injectable currently awaiting FDA approval, is calling for the development of formal clinical guidelines and further research to help avoid adverse patient reactions.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
4
Phase 2 Nemolizumab Trial Opens for CPUO
5


















